PubMed Health⌕ Search

Biomedical subjects

G Komaki

Publications and source records attributed to G Komaki.

38 records · Page 3Linked to original sources

Rapid increase in plasma IL-6 after hemorrhage, and posthemorrhage reduction of the IL-6 response to LPS, in conscious rats: interrelation with plasma corticosterone levels.

To study whether hemorrhage stimulates interleukin-6 (IL-6) production in conscious rats, 30% of the total blood was withdrawn over 3 min through an indwelling venous catheter and the shedblood was reinfused 1 h later. Plasma adrenocorticotropic hormone (ACTH), corticosterone and IL-6 concentration rapidly increased. Plasma ACTH levels peaked at 10 min and corticosterone and IL-6 peaked at 60 min; all started to decrease after reinfusion. In adrenalectomized (ADX) rats with or without a corticosterone pellet implant, there was an inverse relationship between IL-6 and corticosterone concentrations, greatest in ADX rats and lowest in ADX rats in which plasma corticosterone was elevated by crushing the implanted pellet. However, the ADX rats in which plasma corticosterone was maintained at normal or slightly elevated levels showed greater IL-6 responses to hemorrhage and elevated basal plasma IL-6 levels compared to sham-operated control rats. Twenty-four hours after hemorrhage/reinfusion, ACTH, corticosterone, and IL-6 responses to i.v. injection of lipopolysaccharide (LPS) were all reduced compared to the non-hemorrhaged animals, indicating that hemorrhage impaired general host defense. Although very high plasma corticosterone concentrations markedly suppressed the IL-6 response to LPS, in ADX rats in which plasma corticosterone was maintained at slightly higher levels than normal, the reduced IL-6 response to LPS in the posthemorrhage period was not reversed, but enhanced. Thus corticosterone has biphasic effects on the IL-6 response to hemorrhage and the response to LPS during the posthemorrhage period, which has important clinical implications with regard to the optimal dose of glucocorticoid for maintaining the host defense response.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenalectomy↗

Pituitary adenylate cyclase activating polypeptide (PACAP) can cross the vascular component of the blood-testis barrier in the mouse.

Pituitary adenylate cyclase activating polypeptide (PACAP), present in highest concentrations in the hypothalamus and testes, affects the release of LH, FSH, and prolactin, as well as Sertoli cell function. We examined the ability of the 38-amino acid form of PACAP labeled with 125I (I-P38) to cross the vascular component of the blood-testis barrier. The unidirectional influx constant (Ki) was 4.23 x 10(-3) ml/g-minute, which is about 5 times faster than the entry of LH and about 17 times faster than that of serum albumin. Entry occurred in part by a saturable transport system, with 20 micrograms/mouse of unlabeled P38 inhibiting transport by 40%. An analog of peptide T, which like PACAP is related to vasoactive intestinal polypeptide and has been found to have its own saturable transport system into the brain, did not alter the uptake of I-P38 by the testes. A dose of 10 micrograms/mouse, but not of 20 micrograms/mouse, was associated with a contraction of the vascular space of the testes. HPLC confirmed that a small but persistent percentage of the radioactivity recovered from the testes represented intact I-P38. These results suggest that circulating P38 may contribute to the testicular pool of PACAP, which may play an active role in the function of the testes.

Analysis of Variance↗